✦ LIBER ✦

A postmarketing surveillance study of the safety and efficacy of ReFacto® (St Louis-derived active substance) in patients with haemophilia A

✍ Scribed by M. P. Smith; P. Giangrande; H. Pollman; R. Littlewood; C. Kollmer; J. Feingold; The Refacto St Louis Study Group

Book ID: 108772483
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 82 KB
Volume: 11
Category: Article
ISSN: 1351-8216
DOI: 10.1111/j.1365-2516.2005.01131.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, safety and tolerability of rec

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria

✍ H. POLLMANN; D. EXTERNEST; A. GANSER; B. EIFRIG; W. KREUZ; H. LENK; I. PABINGER; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB

Clinical safety surveillance study of th

Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto® utilizing a computer-aided diary: a Nordic multicentre study

✍ P. PETRINI; C. RYLANDER 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Postmarketing surveillance study of KOGE

Postmarketing surveillance study of KOGENATE® Bayer with Bio-Set® in patients with haemophilia A: evaluation of patients’ satisfaction after switch to the new reconstitution system

✍ N. VIDOVIC; R. MUSSO; R. KLAMROTH; M. M. ENRIQUEZ; K. ACHILLES 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

The efficacy and safety of leflunomide i

The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study

✍ J. R. Kalden; M. Schattenkirchner; H. Sörensen; P. Emery; C. Deighton; B. Rozman 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

## Abstract ## Objective To investigate the efficacy and safety of leflunomide beyond 2 years in a multinational, open‐label extension of 2 phase III double‐blind studies. ## Methods Patients with rheumatoid arthritis (RA) who received leflunomide (100 mg/day for 3 days, 10 mg/day or 20 mg/day t

Interim data on long-term efficacy, safe

Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A

✍ L. NEMES; H. POLLMANN; T. BECKER 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

A clinical study assessing the pharmacok

A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine®, a high-purity factor IX concentrate, in patients with severe haemophilia B

✍ T. LISSITCHKOV; M. MATYSIAK; K. ZAVILSKA; P. ŁAGUNA; L. GERCHEVA; A. ANTONOV; N. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB